The NINDS department is offering this grant to bridge the significant funding gap, often called the “Valley of Death,” that impedes the commercialization of medical biotechnology products after SBIR/STTR Phase II awards. This opportunity aims to assist previously funded SBIR/STTR Phase II awardees in achieving critical milestones necessary to advance their products or technologies towards market readiness. Specifically, this grant is for facilitating the transition of pre-clinical research projects to the commercialization stage, particularly for those requiring Federal regulatory approval or bringing complex research tools to market. The initiative strongly encourages partnerships between awardees and third-party investors or strategic partners, with an emphasis on securing independent third-party funding throughout the Phase IIB project period to ensure successful market entry.
Opportunity ID: 355061
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-24-222 |
| Funding Opportunity Title: | NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Pre-Clinical Research (R44 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jun 21, 2024 |
| Last Updated Date: | Jun 21, 2024 |
| Original Closing Date for Applications: | Apr 05, 2027 |
| Current Closing Date for Applications: | Apr 05, 2027 |
| Archive Date: | May 11, 2027 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Some projects initiated with SBIR or STTR funding require considerable financing beyond the SBIR/STTR Phase II award to achieve commercialization. The development of medical biotechnology products is often impeded by a significant funding gap (known as the Valley of Death) between the end of the SBIR/STTR Phase II award and the commercialization stage. The goal of this FOA is to assist applicants in pursuing the next appropriate milestone(s) necessary to advance a product/technology that requires Federal regulatory approval or to bring a complex research tool to market. This opportunity aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NINDS SBIR or STTR awardees and third-party investors and/or strategic partners in the Phase IIB competing renewal. Applicants are strongly encouraged to secure independent third-party funding throughout the Phase IIB project period. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-24-222.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 355061 Full Announcement-PAR-24-222 -> PAR-24-222-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or before January 24, 2025 | PKG00287122 | Aug 05, 2024 | Jan 24, 2025 | View | |
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00289103 | Nov 26, 2024 | Apr 05, 2027 | View |
Package 1
Mandatory forms
355061 RR_SF424_5_0-5.0.pdf
355061 PHS398_CoverPageSupplement_5_0-5.0.pdf
355061 RR_OtherProjectInfo_1_4-1.4.pdf
355061 PerformanceSite_4_0-4.0.pdf
355061 RR_KeyPersonExpanded_4_0-4.0.pdf
355061 RR_Budget_3_0-3.0.pdf
355061 PHS398_ResearchPlan_5_0-5.0.pdf
355061 SBIR_STTR_Information_3_0-3.0.pdf
355061 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
355061 RR_SubawardBudget30_3_0-3.0.pdf
355061 PHS_AssignmentRequestForm_4_0-4.0.pdf
Package 2
Mandatory forms
355061 RR_SF424_5_0-5.0.pdf
355061 PHS398_CoverPageSupplement_5_0-5.0.pdf
355061 RR_OtherProjectInfo_1_4-1.4.pdf
355061 PerformanceSite_4_0-4.0.pdf
355061 RR_KeyPersonExpanded_4_0-4.0.pdf
355061 RR_Budget_3_0-3.0.pdf
355061 PHS398_ResearchPlan_5_0-5.0.pdf
355061 SBIR_STTR_Information_3_0-3.0.pdf
355061 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
355061 RR_SubawardBudget30_3_0-3.0.pdf
355061 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
